-
Incyte Corporation NASDAQ:INCY Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.
Location: 1801 Augustine Cut off, Delaware, 19803-4404, US | Website: www.incyte.com | Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
12.25B
Cash
1.775B
Avg Qtr Burn
N/A
Short % of Float
3.19%
Insider Ownership
2.05%
Institutional Own.
97.43%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer | Approved Quarterly sales | |
Niktimvo™ (axatilimab-csfr) Details Graft-versus-host disease | Approved Quarterly sales | |
Pemazyre® (pemigatinib) Details 8p11 myeloproliferative syndrome | Approved Quarterly sales | |
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details Solid tumor/s, Cancer, Squamous cell carcinoma of the anal canal | BLA Submission | |
Tafasitamab (Monjuvi®) + Lenalidomide & Rituximab Details Follicular lymphoma, Relapsed/ refractory lymphoma | BLA Submission | |
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details Solid tumor/s, Cancer, Non-small cell lung carcinoma | BLA Submission | |
QD Ruxolitinib XR Details Myelofibrosis | NDA FDA meeting | |
Phase 3 Data readout | ||
Povorcitinib (JAK1) Details Hidradenitis suppurativa | Phase 3 Data readout | |
Opzelura™ (ruxolitinib) cream Details Atopic dermatitis | Phase 3 Data readout | |
Povorcitinib (JAK1) Details Vitiligo | Phase 3 Initiation | |
INCB57643 (BETi)+ruxolitinib Details Myelofibrosis | Phase 3 Initiation | |
Ruxolitinib Cream (Opzelura®) Details Cutaneous Lichen Planus | Phase 2 Data readout | |
Ruxolitinib Cream (Opzelura®) Details Hidradenitis suppurativa | Phase 2 Data readout | |
Povorcitinib (JAK1) Details Prurigo nodularis | Phase 2 Data readout | |
ALK2 + ruxolitinib Details Myelofibrosis | Phase 2 Data readout | |
INCB123667 [CDK2 Inhibitor] Details Solid tumor/s | Phase 1 Data readout | |
INCA033989 (mCALR) Details Myelofibrosis | Phase 1 Data readout | |
Parsaclisib + ruxolitinib Details Myelofibrosis | Failed Discontinued | |
INCB99280/INCB99318 PD-L1 (oral) Details Solid tumor/s | Failed Discontinued |